Drug Interactions between Aminatal Plus and pafolacianine
This report displays the potential drug interactions for the following 2 drugs:
- Aminatal Plus (multivitamin, prenatal)
- pafolacianine
Interactions between your drugs
multivitamin, prenatal pafolacianine
Applies to: Aminatal Plus (multivitamin, prenatal) and pafolacianine
ADJUST DOSING INTERVAL: Concomitant administration of folate, folic acid, or folate-containing supplements may reduce the binding of pafolacianine to folate receptors overexpressed on ovarian cancer cells. This may lead to a reduction in the detection of malignant lesions with pafolacianine.
MANAGEMENT: Concomitant use of folate, folic acid, or folate-containing supplements with pafolacianine is not recommended. The manufacturer advises that these supplements should be discontinued 48 hours before the administration of pafolacianine.
References
- (2021) "Product Information. Cytalux (pafolacianine)." Grand River Aseptic Manufacturing
Drug and food interactions
multivitamin, prenatal food
Applies to: Aminatal Plus (multivitamin, prenatal)
ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.
Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.
MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
References
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
- (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.